Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
X
Announcing the new Tapestri Solution for Solid Tumor Oncology Research. Learn More
X
publication

Polyclonal Heterogeneity: The New Norm for Secondary Clinical Resistance to Targeted Monotherapy in Relapsed Leukemia?


Wei, A.H. et al.
Cancer Discovery (2019)
Abstract

In this issue, McMahon and colleagues demonstrate that secondary clinical resistance to the FLT3 inhibitor gilteritinib in relapsed acute myeloid leukemia is often polyclonal and commonly mediated by heterogeneous mutations that activate downstream RAS-MAPK pathways. These findings and recent data from others indicate that emergence of multiple clones, each with distinct mechanisms of resistance, is a common finding at secondary failure of single-agent-targeted therapies for relapsed leukemias..



Authors

Wei, A.H., Roberts, A.W.



VIEW

publication
Distinct patterns of clonal evolution drive myelodysplastic syndrome progression to secondary acute myeloid leukemia
Guess T
Blood Cancer Discovery (2022)
publication
High-throughput single-cell sequencing for retroviral reservoir characterization
Droske LE
BioRxiv (2022)
publication
scTAM-seq enables targeted high-confidence analysis of DNA methylation in single cells
Bianchi A
BioRxiv (2022)
publication
Monitoring of leukemia clones in B-cell acute lymphoblastic leukemia at diagnosis and during treatment by single-cell DNA amplicon sequencing
Meyers S
HemaSphere (2022)
REQUEST QUOTE